Navigation Links
Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
Date:5/28/2009

previous clinical study, a subset of patients with recurrent glioblastoma treated with Cotara achieved a median survival of 38 weeks, a 58% increase over the historical median survival time of 24 weeks for patients treated with standard of care therapy. In this study, 25% of 28 recurrent patients survived for more than a year post-treatment and 10% of patients survived for more than three years. These data are considered a promising development in this deadly disease. Cotara has been granted orphan drug status and fast track designation for the treatment of glioblastoma multiforme and anaplastic astrocytoma by the U.S. Food and Drug Administration. A Phase I dosimetry trial in GBM patients in the U.S. has completed patient enrollment and a Phase II safety and efficacy trial in GBM patients in India is ongoing. For more information on the trials, visit www.clinicaltrials.gov.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and serious virus infections. The company is pursuing three separate clinical programs in cancer and hepatitis C virus (HCV) infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs,
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
2. Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results
3. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
4. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
5. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
6. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
7. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
8. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
9. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
10. Poniard Pharmaceuticals Announces Positive Efficacy and Safety Data From Phase 2 Clinical Trial of Picoplatin in Men With Metastatic Prostate Cancer
11. Verus Pharmaceuticals Announces a Lawsuit Against AstraZeneca AB and Tika Lakemedel AB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014 One week ahead ... Worker Safety announced today it will extend compensation benefits ... months’ wages for workers displaced as a result of ... Alliance inspections have resulted in the closure of five ... five cases, raising immediate safety concerns. In May, the ...
(Date:7/10/2014)... 2014 According to a new ... Platforms (Land, Airborne, Naval), Application (Software Defined Radios, ... Geography (North America, Asia-Pacific, Europe, the Middle East ... by MarketsandMarkets, the market is estimated to be ... register a CAGR of 5.56% to reach $39.52 ...
(Date:7/10/2014)... In his latest blog post at http://www.perwickstrom.com , ... Wickstrom has listed 5 ways to follow-up without being ... get information or sometimes even just return an inquiry, ... a skill that most people don’t have,” commented Per ... dialogue moving without coming across as annoying – let ...
(Date:7/10/2014)... Creek, MI (PRWEB) July 10, 2014 ... alcohol treatment program that gets clients off to a ... recovery they can believe in, has launched a new ... , The new section highlights:, , ... Diagnostic and Statistic Manual of Mental Disorders (DSM-IV), including ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Ivalua, ... latest results of the 4th “Trending in Procurement” ... model. , Every day multinational corporations process ... expense forms etc. To meet this challenge, more ... suites which can be defined as a suite ...
Breaking Medicine News(10 mins):Health News:Alliance for Bangladesh Worker Safety to Double Compensation for Displaced Factory Workers; Members Vote to Extend Wage Benefits from Two to up to Four Months 2Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Per Wickstrom’s Latest Blog Post Lists 5 Ways to Follow-up Without Being Annoying 2Health News:Latest A Forever Recovery Launches Eating Disorders Section on Website 2Health News:‘Source-to-Pay’ e-Procurement Is Real Performance Driver for Purchasing Departments 2Health News:‘Source-to-Pay’ e-Procurement Is Real Performance Driver for Purchasing Departments 3
... Hospitality Solutions with Pro:Idiom , Enable MSOs to ... R.L. Drake , an American ... highly innovative communications solutions for over 65 years, has ... cable transcoders to cable operators in the United States ...
... April 1, GlaxoSmithKline (NYSE: GSK ... regulatory applications to expand the use of TYVERB(R)/TYKERB(R) ... as a first-line therapy regimen combined with anti-hormonal ... breast cancer in Europe and the United States.The ...
... low-level shoulder separations can commonly be treated nonsurgically and ... in the April 2009 issue of the Journal ... JAAOS ) finds that many surgeons still disagree on ... fall in between. , , Shoulder separations, clinically ...
... an important contribution to future clinical therapeutic approaches. The ... Nature and will be a central topic of ... which will take place in Munich from April 2nd ... mechanisms of blood formation (hematopoiesis) will be presented in ...
... Organization for disAbilities Resources champions company,s effortsGAITHERSBURG, Md., ... Disability Matters Award in the category of Work ... supporting people with disabilities and their families. The ... and Springboard Consulting. The integrated food and facilities ...
... mid-level, common injury ROSEMONT, Ill., April 1 While low-level shoulder ... surgery, a literature review published in the April 2009 issue of ... ( JAAOS ) finds that many surgeons still disagree ... in between., , ...
Cached Medicine News:Health News:Drake Nabs 'Suite Deal' as Distributor of Pro:Idiom(R) Hospitality Solution to U.S. and Canadian Cable Operators 2Health News:GSK Submits TYVERB(R)/TYKERB(R) (lapatinib) for First-Line Treatment of Metastatic Breast Cancer in Europe, US 2Health News:GSK Submits TYVERB(R)/TYKERB(R) (lapatinib) for First-Line Treatment of Metastatic Breast Cancer in Europe, US 3Health News:GSK Submits TYVERB(R)/TYKERB(R) (lapatinib) for First-Line Treatment of Metastatic Breast Cancer in Europe, US 4Health News:GSK Submits TYVERB(R)/TYKERB(R) (lapatinib) for First-Line Treatment of Metastatic Breast Cancer in Europe, US 5Health News:Healing a shoulder separation 2Health News:Last step leading to blood cell formation elucidated 2Health News:Sodexo Receives 2009 Disability Matters Award 2Health News:Sodexo Receives 2009 Disability Matters Award 3Health News:Healing a Shoulder Separation 2Health News:Healing a Shoulder Separation 3
(Date:7/10/2014)... , July 10, 2014 CVS Caremark Corporation (NYSE: ... directors has approved a quarterly dividend of $0.275 (27.5 cents) ... payable on August 1, 2014, to holders of record on ... CVS Caremark is dedicated to helping people on their ... in the United States . Through the ...
(Date:1/15/2014)... and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the addition ... Analysis, Size, Share, Growth, Trends And Forecast, 2013 - ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Dental ... order to treat dental impairments, for tooth restoration and ...
(Date:1/15/2014)... THOUSAND OAKS, Calif. , Jan. 15, 2014 ... and Amgen (NASDAQ: AMGN ) announced ... to jointly discover and validate new therapeutic targets ... (IBD), a chronic disorder that affects millions worldwide. ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
... Semafore Pharmaceuticals Inc.,announced today on the occasion of ... Conference in San Francisco that its,integrin-targeted PI3 kinase ... agents in vitro and in vivo (poster,C207). ... of prostate cancer cells with combinations of docetaxel ...
... IRVINE, Calif., Oct. 26 IDM Pharma, Inc.,(Nasdaq: ... the development of,innovative cancer therapies, today announced details ... pipeline compounds to be,presented at upcoming medical congresses. ... Mifamurtide (L-MTP-PE):, Connective Tissue Oncology Society (CTOS) ...
Cached Medicine Technology:Semafore's PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents 2IDM Pharma Announces Upcoming Clinical Data Presentations 2IDM Pharma Announces Upcoming Clinical Data Presentations 3IDM Pharma Announces Upcoming Clinical Data Presentations 4
... lab with the OLA2500 High Speed Sorter ... sorting requirements. As a front-end sample-processor, the ... primary sample tubes to their destination racks ... eliminate sample-handling errors. Post-analytical archiving to any ...
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
Similar to Model 530, but just 37 inches long and with only one drape....
2-ply material consisting of polyethylene film inner layer and non-woven outer layers....
Medicine Products: